News | Heart Valve Technology | July 26, 2018

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

Slow progression of disease may mask symptoms until damage cannot be fully repaired

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

July 26, 2018 — The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many patients do not undergo surgical intervention until it is too late to completely reverse damage caused by mitral valve disease. The study is posted online in The Annals of Thoracic Surgery.

“This study shows that a significant number of patients are still referred for mitral valve surgery later than they should be,” said James S. Gammie, M.D., from the University of Maryland School of Medicine in Baltimore. “In these cases, the malfunctioning mitral valve has caused significant damage to the heart and/or lungs, and while an operation can be performed, long-term outcomes will be compromised, to some extent.”

Gammie, Vinay Badhwar, M.D., from West Virginia University in Morgantown, W. Va., and colleagues analyzed data from The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) in order to determine trends related to current mitral valve operations in North America. The ACSD contains more than 6.5 million cardiac surgery procedure records, representing more than 90 percent of all adult cardiac surgery hospitals across the United States and Canada.

The researchers identified 87,214 patients at 1,125 centers who had isolated primary mitral valve operations from July 2011 to September 2016. The average age of patients in this group was 64 years; half were female. During the study period, the number of mitral valve operations performed per year increased by 24 percent, from 14,442 in 2011 to 17,907 in 2016. There was a 44 percent increase in primary mitral operations performed for degenerative disease, the most common form of mitral valve disease in the United States.

“This suggests that the mitral valve disease may have reached a chronic stage prior to referral for operation, which means that heart and lung damage may not be fully reversible,” explained Badhwar. “In these patients, their symptoms may improve after surgery, but their life expectancy may be reduced.”

The mitral valve is the inflow valve between the lungs and the left ventricle, the main pumping chamber of the heart. This valve allows blood to enter the heart from the lungs when the heart muscle is relaxing and also prevents backflow of blood when the heart squeezes. Mitral valve diseases include mitral regurgitation (leaking) and mitral stenosis (narrowing), which may cause fatigue and shortness of breath.

“Once the leakage is severe, heart damage may result, thus mitral valve operation is recommended,” said Badhwar. “The preferred operation is mitral repair, whenever possible. If performed in a timely manner, the patient’s heart function and life expectancy may return to normal.”

In this study, the data showed that the overall repair rate was 65.6 percent (57,244) and the replacement rate was 34.4 percent (29,970). Overall operative mortality was 2 percent (1,762).

“We found that the number of operations performed for mitral valve disease is growing faster than any other category of heart operation and that the results were excellent with low risks of death and complications,” said Gammie.

The researchers also revealed that while the prevalence of mitral valve disease and the number of mitral valve operations performed per year are increasing, overall aortic valve operations were performed 1.6 times more commonly than mitral valve operations during the study period.

“This may suggest important under-referral and under-treatment of mitral valve disease, which may be related to the slower progression of signs and symptoms of mitral compared to aortic disease, as well as potential lack of adherence to guidelines for intervention,” said Gammie. “So although contemporary outcomes are excellent, there remains an important and substantial opportunity to improve results for patients with mitral valve disease by following established guidelines and encouraging earlier referral for operation.”

For more information: www.annalsthoracicsurgery.org

Reference

Gammie J.S., Chikwe J., Badhwar V., et al. "Isolated Mitral Valve Surgery: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis." Annals of Thoracic Surgery, published online July 18, 2018. https://doi.org/10.1016/j.athoracsur.2018.03.086


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now